Erratum: SGLT2 inhibitors in combination therapy: From mechanisms to clinical considerations in type 2 diabetes management. (Diabetes Care (2018) 41 (1543–1556) DOI: 10.2337/dc18-0588)
| Autor: | van Baar, Michaël J. B., van Ruiten, Charlotte C., Muskiet, Marcel H. A., van Bloemendaal, Liselotte, IJzerman, Richard G., van Raalte, Daniël H. |
|---|---|
| Přispěvatelé: | Internal medicine, Neurology, AGEM - Endocrinology, metabolism and nutrition, ACS - Diabetes & metabolism |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Zdroj: | van Baar, M J B, van Ruiten, C C, Muskiet, M H A, van Bloemendaal, L, IJzerman, R G & van Raalte, D H 2019, ' Erratum: SGLT2 inhibitors in combination therapy: From mechanisms to clinical considerations in type 2 diabetes management. (Diabetes Care (2018) 41 (1543–1556) DOI: 10.2337/dc18-0588) ', Diabetes Care, vol. 42, no. 10, pp. 2015 . https://doi.org/10.2337/dc19-10a Diabetes Care, 42(10). American Diabetes Association Inc. |
| ISSN: | 0149-5992 |
| DOI: | 10.2337/dc18-0588) |
| Popis: | In the article cited above, Fig. 3 was replaced. The data in the HbA1c (%) panel under 8.9 baseline was corrected. The online version of the article (https://doi.org/10.2337/dc18-0588) has been corrected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|